GPP
TGTX icon

Great Point Partners’s TG Therapeutics TGTX Stock Holding History

Great Point Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,000,000
Closed -$9.84M – 40
2020
Q1 		$9.84M Buy
+1,000,000
New +$12.6M 1.03% 24

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Great Point Partners's TGTX Position: Q4 2020 in Review

Great Point Partners sold out of TG Therapeutics (TGTX) in Q4 2020, closing a stake of 1,600,000 shares — an estimated $42.8M sold.

Great Point Partners first reported a position in TGTX in Q3 2018 and held it in 6 quarters. The position peaked at $64.7M in Q2 2020. 247 funds tracked by Wall St. Rank hold TGTX as of Q4 2020.

  • Great Point Partners reported no remaining TG Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Great Point Partners sold 1,600,000 TG Therapeutics shares in Q4 2020, an estimated $42.8M.
  • Great Point Partners first reported a position in TG Therapeutics in Q3 2018 and held it in 6 quarters.
  • Great Point Partners's TG Therapeutics position peaked at $64.7M in Q2 2020.
  • 247 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2020.

Based on Great Point Partners's 13F filing for Q4 2020, filed 16 Feb 2021.